Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

A shorter course of prophylactic antibiotics, or even no course at all, appeared to be noninferior to longer courses in ...

In moderate to severe Crohn's disease, a network meta-analysis suggested that TNF inhibitor-based therapy was the most ...

Gastroenterologist Dr Salhab warns that liver cirrhosis can lead to overt hepatic encephalopathy, impacting brain function and overall well-being.

FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on ...

Pooled data show that no or shorter antibiotic prophylaxis for upper GI bleeding in cirrhosis is very likely noninferior to longer courses for all-cause mortality, challenging long-standing advice.

Elexacaftor–tezacaftor–ivacaftor was linked to a 72% lower risk of severe liver complications in cystic fibrosis patients, ...

Prosecutors charged Blair Hamilton Hayes, 61 with causing the death of 47-year-old Emma Jean Teague this March ...

Liver failure syndromes are characterized by a dysregulated immune response leading to immune paralysis. Adrenomedullin (ADM) ...